je.st
news
Tag: mercks
Premarket Biotech Digest: Mylan's Perrigo Bid, MannKind Rallies, Merck's Setback
2015-11-13 23:38:00| Biotech - Topix.net
Click this Mylan shares are up more than 11% in pre-market trading today as the company's takeover bid for Perrigo is likely to fail. MYL had launched a hostile bid for PRGO earlier this year.
Tags: bid
digest
biotech
setback
Mercks KEYTRUDA (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
2015-10-26 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline results from the KEYNOTE-010 study of KEYTRUDA (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating that the trial met its primary objective. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
shows
express
cell
Results from Mercks Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
2015-10-06 01:01:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-nave and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA Expands Approval Of Merck's Keytruda To Lung Cancer
2015-10-04 19:17:21| Biotech - Topix.net
The U.S. Food and Drug Administration on Friday approved Merck & Co Inc's immunotherapy, Keytruda, for patients with the most common form of lung cancer whose tumors produce a specific biological marker. The FDA approval for Keytruda in advanced non-small cell lung cancer is for patients whose tumors express PD-L1, a protein targeted by the drug, and includes a companion diagnostic, made by a unit of Agilent Technologies Inc, to measure those protein levels.
Tags: approval
cancer
lung
expands
MARIZEV (Omarigliptin), Mercks Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
2015-09-28 13:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved MARIZEV (omarigliptin) 25 mg and 12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes. Japan is the first country to have approved omarigliptin. Language: English Contact: Media Contacts:Pam Eisele, 267-305-3558orMichael Close, 310-617-1067orKristen Drake, 908-236-4223orInvestor Contacts:Justin Holko, 908-740-1879orTeri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »